Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly In Asia Expansion Overdrive

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Eli Lilly opened a brand new Asian office and unveiled a major expansion at a second office in as many days as part of a company-wide shift to a new collaborative research and development model, company officials told PharmAsia News

You may also be interested in...



Global Spread Of Technologies, West’s Economic Downturn And East’s Rise Will Fundamentally Change Pharma Giants By 2020

BEIJING - A number of coinciding trends - ranging from the worldwide spread of technologies that can link up scientists and research models from Boston to Beijing to the decline of productivity at traditional drug R&D labs to the rise of the Eastern economic powers - will fundamentally change the structure of the West's pharmaceutical giants and their development of new molecules

Global Spread Of Technologies, West’s Economic Downturn And East’s Rise Will Fundamentally Change Pharma Giants By 2020

BEIJING - A number of coinciding trends - ranging from the worldwide spread of technologies that can link up scientists and research models from Boston to Beijing to the decline of productivity at traditional drug R&D labs to the rise of the Eastern economic powers - will fundamentally change the structure of the West's pharmaceutical giants and their development of new molecules

Lilly Asian Ventures Looking For Chinese Companies To Invest In

SHANGHAI - Lilly Asian Ventures will focus on directly investing into individual companies under its second phase of investment in China, the firm announced Nov.7 in Shanghai

Related Content

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel